POS1098 PREVALENT COMORBIDITIES ASSOCIATED WITH CLINICALLY DIAGNOSED OSTEOARTHRITIS: A CASE-CONTROL ANALYSIS INCLUDING 1,936,792 PEOPLE

Background: Osteoarthritis (OA) is the most common form of arthritis and a major cause pain disability worldwide. Individuals with OA have increased cardiovascular morbidity mortality, other comorbidities are also more amongst them than in general population. In this study, we examined prevalence timing diagnosis co-morbidities prior to clinical OA. Objectives: To determine odds newly diagnosed cases versus matched controls up 10 years diagnosis. Methods: Case-control study people registered Information System for Research Primary Care (SIDIAP). SIDIAP includes primary care records covering over 80% population Catalonia, Spain. Participants an incident OA, based on ICD-10-CM disease codes, were 4 by age (within 2 years), gender practice. The first date used index date, using same retrospectively review comorbidities. Patients required at least 3 continuous registration date. A total 57 considered, knowledge consensus. Descriptive statistics obtain demographic information about controls. Counts any comorbidity calculated, univariable multivariable logistic regression calculate ratios (ORs) 95% confidence intervals (CIs) individual adjusted age, socio-economic status. Results: total, there 455,494 1,481,298 similar regards deprivation level. time was 77% (n= 350,913) 61% 909,497) results from analysis [Table 1] showed that patients had higher many 1 year their compared They likely be another musculoskeletal condition followed neuro-psychiatric metabolic conditions. Conversely, less cancer Table 1. Multivariable Co-morbidity 1-year (OR, CI) 10-year Musculoskeletal conditions Ankylosing Spondylosis 3.12 (2.41, 4.05 ) 1.27 (1.12, 1.43 Fibromyalgia 4.24 (3.96, 4.54 1.85 (1.80, 1.91 Rheumatoid Arthritis 2.67 (2.40, 2.97 (1.20, 1.34 Back/ neck 2.41 (2.38, 2.45 1.76 (1.75, 1.78 Neuro-psychiatric Anxiety 1.69 (1.65, 1.73 1.23 (1.22, 1.24 Depression 1.87 (1.81, 1.93 1.25 (1.24, Irritable Bowel Syndrome 1.90 (1.71, 2.11 1.28 Migraine 1.81 (1.69, 1.94 Cancer Leukaemia 1.07 (0.88, 1.30) 0.91 (0.82, 1.00) Lymphoma 0.84 (0.68, 1.03) 0.90 0.99 Solid malignancy 0.95 (0.91, (0.93, 0.97 Other medical Stroke 1.15 (1.10, 1.20 Hypertension 1.70 (1.68, 1.74 1.26 (1.25, Diabetes (1.30, 1.38 (1.06, 1.09 Obesity 1.96 (1.92, 2.01 1.60 (1.58, 1.62 Conclusion: multiple chronic Our found these (particularly conditions) occur prior, except lymphoma solid malignancy. These help us further understand relationship development Disclosure Interests: Arani Vivekanantham: None declared, Daniel Prieto-Alhambra: Danielle E Robinson Grant/research support from: Dr. Prieto-Alhambra reports grants AMGEN, grants, non-financial UCB Biopharma, Les Laboratoires Servier, outside submitted work; Janssen, behalf IMI-funded EHDEN EMIF consortiums, Synapse Management Partners supported training programmes organised DPA’s department open external participants.